Gilead's Truvada PR campaign created black market among Florida MSMs, says AHF

Share this article:

The AIDS Healthcare Foundation accused Gilead of inadvertently creating a "black market" for its Truvada HIV drug by running a marketing campaign aimed at persuading the FDA to approve the blockbuster for prophylactic use.

Florida's Agency for Healthcare Administration told the AIDS Healthcare Foundation (AHF) that a spike in demand for Truvada for prophylactic use is behind a recent state policy change requiring pharmacy claims for antiretrovirals to confirm HIV/AIDS or Hepatitis B diagnosis.

"The fact that a black market has cropped up in response to Gilead's campaign to obtain FDA approval for Truvada shows what a dangerous game Gilead is playing," said AHF president Michael Weinstein in a statement. "The increased demand that has been created by Gilead's reckless push to have Truvada approved prematurely for this new use is only a preview of what is to come. If the company succeeds, Gilead will have free reign to market Truvada to HIV-negative individuals. This will open up a demand for the drug that will inevitably create an even bigger black market, ultimately resulting in increased infections, viral resistance and a huge step backwards in efforts to fight the pandemic."

The watchdog group-slash-service provider has opposed Gilead's efforts to obtain marketing approval for Truvada as pre-exposure prophylaxis, based on its iPrex study of HIV-negative but high-risk men who have sex with men (MSMs) that found the once-daily pill could cut the risk of HIV infection by 44% in that demographic. Critics point to subsequent studies that show the drug to be less effective, due mainly to poor adherence, and 618 doctors or advocates recently signed letters to FDA and Gilead expressing concerns that prophylactic use of the drug could lead to more risky behavior by some users. AHF has even set up a website to fight the indication, at www.nomagicpills.org.

The drug generated $2.6 billion in revenue last year, with at least one analyst suggesting, as AHF noted, that an indication for prophylactic use could add another billion in sales.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...